No press releases found.
BGM Group Calls July EGM to Overhaul Share Capital and Governance Structure
TipRanks (Wed, 17-Jun 7:13 PM ET)
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
BGM Group Ltd. - Class A trades on the NASDAQ stock market under the symbol BGM.
As of June 18, 2026, BGM stock price declined to $0.37 with 144,906 million shares trading.
BGM has a beta of 1.89, meaning it tends to be more sensitive to market movements. BGM has a correlation of 0.02 to the broad based SPY ETF.
BGM has a market cap of $73.23 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that BGM belongs to (by Net Assets): ONEQ, GXC.
BGM has underperformed the market in the last year with a return of -97.2%, while the SPY ETF gained +26.9%. In the last 3 month period, BGM fell short of the market, returning -57.9%, while SPY returned +13.5%. However, in the most recent 2 weeks BGM has outperformed the stock market by returning +12.3%, while SPY returned -1.1%.
BGM support price is $.34 and resistance is $.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGM shares will trade within this expected range on the day.
